ANIX
Anixa Biosciences Inc

10,534
Mkt Cap
$112.58M
Volume
226,209.00
52W High
$5.46
52W Low
$2.07
PE Ratio
-9.29
ANIX Fundamentals
Price
$3.20
Prev Close
$3.42
Open
$3.41
50D MA
$4.17
Beta
1.19
Avg. Volume
166,075.79
EPS (Annual)
-$0.3936
P/B
6.33
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Anixa Biosciences from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Friday...
MarketBeat·15d ago
News Placeholder
Anixa Biosciences Shares Jump Over 15% In After-Hours Trading Here's Why
Anixa Biosciences shares surged in after-hours trading after presenting clinical trial data for its investigational breast cancer vaccine.read more...
Benzinga·15d ago
News Placeholder
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants Anixa Biosciences Announces...
PR Newswire·16d ago
News Placeholder
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025...
PR Newswire·17d ago
News Placeholder
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Zacks Research
Zacks Research downgraded Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday...
MarketBeat·1mo ago
News Placeholder
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future...
PR Newswire·1mo ago
News Placeholder
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s...
PR Newswire·1mo ago
News Placeholder
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11...
PR Newswire·2mo ago
News Placeholder
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic PR Newswire SAN JOSE...
PR Newswire·2mo ago
<
1
2
...
>

Latest ANIX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.